Detalles de la búsqueda
1.
Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.
Br J Clin Pharmacol
; 83(8): 1688-1700, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28156017
2.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood
; 119(1): 55-63, 2012 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22001391
3.
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Haematologica
; 99(4): 672-8, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362550
4.
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Blood
; 117(12): 3302-10, 2011 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21239698
5.
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Br J Haematol
; 158(2): 198-207, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22594769
6.
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica
; 97(11): 1736-42, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22733022
7.
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Blood
; 113(20): 4841-52, 2009 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19109557
8.
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Haematologica
; 96(11): 1619-26, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21791475
9.
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Clin Cancer Res
; 14(10): 3077-82, 2008 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18483374
10.
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Cancer Chemother Pharmacol
; 83(2): 319-328, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30456480
11.
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leuk Res
; 32(1): 71-7, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17640728
12.
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Clin Cancer Res
; 13(15 Pt 1): 4467-73, 2007 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17671131
13.
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Clin Transl Sci
; 11(4): 435-443, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29702736
14.
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Leuk Res
; 31(9): 1165-73, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17324462
15.
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Clin Cancer Res
; 23(14): 3592-3600, 2017 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28174232
16.
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
Clin Cancer Res
; 23(21): 6421-6429, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28751440
17.
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Clin Cancer Res
; 11(23): 8403-12, 2005 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16322302
18.
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Clin Cancer Res
; 9(1): 307-15, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12538483
19.
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Clin Cancer Res
; 10(11): 3577-85, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15173063
20.
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia.
Leuk Lymphoma
; 53(4): 660-4, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21942284